[July 24, 2014]

Advanced Biological Laboratories (ABL) and Roche Diagnostics International Renew and Extend their Collaboration Agreement to Promote their Next-Generation Sequencing, Genotyping and Drug Resistance Products

Advanced Biological Laboratories (ABL) today announced the renewal of a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories.

This collaboration agreement is intended to develop a strategy to promote ABL products especially its next-generation sequencing platform DeepChek® together with Roche's next generation sequencing systems (GS Junior and GS FLX+ Sequencing Systems) for molecular virology. The principal objectives of the collaboration are to provide our mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity and meaningful genotyping and drug resistance reporting for personalized healthcare.

The collaboration has been extended from HIV to viral hepatitis B and C.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer dignostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About ABL

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek® and HepatiC™, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products received CE-marking for IVD use. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. More at www.ablsa.com.

All trademarks used or mentioned in this release are protected by law.

[ Back To TMCnet.com's Homepage ]